Back to top
more

Zynex (ZYXI)

(Delayed Data from NSDQ)

$1.73 USD

1.73
4,989,079

+0.46 (36.36%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $1.70 -0.03 (-1.45%) 5:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of -60.00% and -17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of -65% and 15.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of -122.22% and 14.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial

by Zacks Equity Research

Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.

Zacks Equity Research

Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of 40% and 0.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

by Zacks Equity Research

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Zacks Equity Research

Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of -50% and 3.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy

by Zacks Equity Research

Zynex (ZYXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Zynex (ZYXI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Should Value Investors Buy Zynex (ZYXI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Zynex (ZYXI) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Are Investors Undervaluing Zynex (ZYXI) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

3 Reasons Growth Investors Will Love Zynex (ZYXI)

by Zacks Equity Research

Zynex (ZYXI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q3 Earnings Match Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Does Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Zynex Inc. (ZYXI) points to a 65.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Q3 Earnings Top Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 30.77% and -1.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.